What amount sold does Cingulate Therapeutics report in Form D filings?

The latest linked filings report $33M sold across 2 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Cingulate Therapeutics's most recent SEC filing?

Cingulate Therapeutics's most recent Form D filing was on 2020-06-29.

How many investors does Cingulate Therapeutics have?

The most recent Form D filing lists 203 investor(s).

What type of securities does Cingulate Therapeutics offer?

Cingulate Therapeutics's SEC Form D filings indicate equity, debt offerings.

Cingulate Therapeutics

CIK: 0001593151·Pharmaceuticals·Kansas City, KS·Limited Liability Company

Reported Sold

$33,000,000

Total Filings

Identified Offerings

Last Filed

Jun 29, 2020

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Jun 29, 2020Form D/A — Amendment

Reported sold: $26,200,000 · Target: Indefinite

Rule 506(b)·203 investors·Section 4(a)(5)

Changed: Reported amount sold, Reported investors

Jul 3, 2019Form D/A — Amendment

Reported sold: $19,200,000 · Target: Indefinite

Rule 506(b)·156 investors·Section 4(a)(5)

Changed: Reported amount sold, Reported investors

Jul 11, 2018Form D — New notice

Reported sold: $15,600,000 · Target: Indefinite

Rule 506(b)·133 investors·Section 4(a)(5)

Jan 16, 2018Form D/A — Amendment

Reported sold: $6,800,000 · Target: Indefinite

Rule 506(b)·116 investors·Section 4(a)(5)

Changed: Reported amount sold, Reported investors

May 2, 2017Form D/A — Amendment

Reported sold: $3,100,000 · Target: Indefinite

Rule 506(b)·65 investors·Section 4(a)(5)

Changed: Reported amount sold, Reported investors

Jan 19, 2016Form D/A — Amendment

Reported sold: $75,000 · Target: Indefinite

Rule 506(b)·2 investors·Section 4(a)(5)

Nov 27, 2013Form D — New notice

Reported sold: $75,000 · Target: Indefinite

Rule 506(b)·2 investors·Section 4(a)(5)

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

203

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

71%

Latest reported sold across 2 identified offerings

$33,000,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Arthur B Straughn

Related Person

Appears on 7 filings

Craig Steven Gilgallon

Related Person

Appears on 7 filings

Matthew N Brams

Related Person

Appears on 7 filings

Patrick J Gallagher

Related Person

Appears on 7 filings

Laurie A Myers

Related Person

Appears on 6 filings

Raul R Silva

Related Person

Appears on 5 filings

Shane j Schaffer

Related Person

Appears on 4 filings

Louis George Van Horn

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jun 29, 2020	Amendment	Indefinite	$26,200,000	203
Jul 3, 2019	Amendment	Indefinite	$19,200,000	156
Jul 11, 2018	New	Indefinite	$15,600,000	133
Jan 16, 2018	Amendment	Indefinite	$6,800,000	116
May 2, 2017	Amendment	Indefinite	$3,100,000	65
Jan 19, 2016	Amendment	Indefinite	$75,000	2
Nov 27, 2013	New	Indefinite	$75,000	2

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Vesalius Longevity Labs Inc.

Pharmaceuticals

Offering target: $30,112,500

Filed Nov 3, 2026